Department of Medicine/Diabetology and Endocrinology, Kuopio University Hospital, Kuopio, Finland.
Curr Med Res Opin. 2010 Oct;26(10):2431-9. doi: 10.1185/03007995.2010.512447.
Several different durable or disposable insulin pen delivery devices are currently available, and newer, improved devices are being introduced. One prefilled insulin device, FlexPen (FP), has recently been improved (known as the Next Generation FlexPen (NGFP) in Europe or the improved FlexPen in the United States). The aim of this review is to summarize the clinical and health economic data of FP and its modified version.
Relevant clinical and health economic terms relating to insulin pens were used to search Medline for studies and other publications involving FP and NGFP.
Sixteen publications investigating FP and/or the NGFP were identified. Patients prefer FP and are more confident with its use in comparison to vial/syringe insulin administration: in a study of 105 patients with type 1 or type 2 diabetes, 85% of patients found FP to be more discreet for use in public than a syringe, 74% of patients found FP to be easier to use overall and 82% of patients had more confidence with setting the correct dose with FP. Four publications investigated the dosing accuracy of FP or NGFP: all studies found the study doses for both were within ISO-specified limits. Pharmacoeconomic issues with insulin pen devices were identified in four papers, and switching to FP from vial/syringe was found to increase treatment adherence from 59% to 68% (p < 0.01), as measured by medication possession ratio. Switching to FP is also a cost-effective option for patients. Mean all-cause annual treatment (-$1748/patient, p < 0.01), hypoglycaemia-attributable costs (-$908/patient, p < 0.01), and other diabetes-attributable costs (-$643/patient, p < 0.01) were reduced following the switch from vial/syringe.
Some limitations of traditional insulin administration devices can be overcome with insulin pen devices. FP is a prefilled disposable pen that has been modified to further improve characteristics beneficial to patient insulin administration.
目前有几种不同的耐用或一次性胰岛素笔式注射器输送装置,并且正在引入更新、改进的装置。一种预充式胰岛素装置,FlexPen(FP),最近已经得到改进(在欧洲称为下一代 FlexPen(NGFP),在美国称为改进的 FlexPen)。本综述的目的是总结 FP 及其改良版的临床和健康经济学数据。
使用与胰岛素笔相关的相关临床和健康经济学术语,在 Medline 上搜索涉及 FP 和 NGFP 的研究和其他出版物。
确定了 16 篇研究 FP 和/或 NGFP 的出版物。患者更喜欢 FP,并且在使用它与使用小瓶/注射器胰岛素相比时更有信心:在一项涉及 105 名 1 型或 2 型糖尿病患者的研究中,85%的患者发现 FP 在公共场合使用比注射器更隐蔽,74%的患者发现 FP 总体上更容易使用,82%的患者对使用 FP 设置正确剂量更有信心。有 4 篇文献研究了 FP 或 NGFP 的剂量准确性:所有研究都发现,这两种研究剂量都在 ISO 规定的范围内。在 4 篇论文中发现了胰岛素笔式注射器的药物经济学问题,与从小瓶/注射器切换到 FP 相比,患者的治疗依从性从 59%增加到 68%(p <0.01),这是通过药物占有比例来衡量的。对于患者来说,切换到 FP 也是一种具有成本效益的选择。平均所有原因年度治疗费用(-1748 美元/患者,p <0.01)、低血糖相关成本(-908 美元/患者,p <0.01)和其他糖尿病相关成本(-643 美元/患者,p <0.01)在从小瓶/注射器切换到 FP 后均有所降低。
一些传统胰岛素给药装置的局限性可以通过胰岛素笔式注射器装置来克服。FP 是一种预充式一次性笔,已得到改进,以进一步改善对患者胰岛素给药有益的特性。